Last 48 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.79 | 27.28 | 17.49 | 17.43 | 52.97 | 48.81 | 50.67 | 55.87 | 58.79 | 66.44 | 88.19 | 51.25 | 42.35 | 38.55 | 75.46 | 60.28 | 132.35 | 80.15 | 54.46 | 164.28 | 190.66 |
| — | -44.1% | -65.5% | -68.8% | -9.9% | -26.5% | -42.6% | +9.0% | +38.8% | +72.4% | +16.9% | -15.0% | -68.0% | -51.9% | +38.6% | -63.3% | -30.6% | +108.4% | -38.8% | +288.5% | +103.2% | |
| P/S Ratio | 3.02 | 3.08 | 2.91 | 4.51 | 6.75 | 7.21 | 7.92 | 8.08 | 7.30 | 7.40 | 6.94 | 6.58 | 5.73 | 5.52 | 5.47 | 5.34 | 5.15 | 4.40 | 4.13 | 5.26 | 4.88 |
| — | -57.2% | -63.3% | -44.2% | -7.5% | -2.7% | +14.2% | +22.7% | +27.3% | +34.1% | +26.8% | +23.3% | +11.3% | +25.5% | +32.5% | +1.4% | +5.5% | -17.2% | -17.0% | +4.8% | +2.0% | |
| P/B Ratio | 2.61 | 2.45 | 2.52 | 3.59 | 5.83 | 6.18 | 7.08 | 6.71 | 6.05 | 5.95 | 5.55 | 5.03 | 4.37 | 4.07 | 4.26 | 3.99 | 3.80 | 3.16 | 3.11 | 3.81 | 3.67 |
| — | -60.4% | -64.4% | -46.4% | -3.7% | +3.9% | +27.7% | +33.4% | +38.4% | +46.1% | +30.2% | +26.0% | +15.1% | +28.8% | +37.2% | +4.9% | +3.5% | -16.5% | -19.2% | +8.2% | +8.6% | |
| P/FCF | 19.08 | 18.25 | 12.39 | 137.15 | 35.20 | 31.41 | 36.59 | 106.37 | 28.61 | 44.64 | 43.43 | — | 30.93 | 39.57 | 43.57 | 262.11 | 27.49 | 46.79 | 66.32 | — | 71.95 |
| — | -41.9% | -66.1% | +28.9% | +23.0% | -29.6% | -15.8% | — | -7.5% | +12.8% | -0.3% | — | +12.5% | -15.4% | -34.3% | — | -61.8% | +7.6% | +132.6% | — | +185.6% | |
| EV / EBITDA | 13.42 | 19.08 | 12.31 | 18.15 | 24.35 | 28.16 | 37.21 | 33.09 | 38.38 | 34.03 | 28.90 | 29.05 | 26.98 | 25.10 | 25.85 | 25.36 | 25.27 | 21.63 | 20.58 | 24.99 | 22.94 |
| — | -32.2% | -66.9% | -45.1% | -36.6% | -17.3% | +28.7% | +13.9% | +42.2% | +35.6% | +11.8% | +14.6% | +6.8% | +16.0% | +25.6% | +1.5% | +10.2% | -11.5% | -6.4% | +0.1% | -28.7% | |
| EV / EBIT | 18.61 | 19.08 | 16.32 | 20.63 | 40.01 | 38.20 | 41.64 | 45.29 | 49.74 | 44.41 | 61.04 | 40.50 | 41.09 | 31.94 | 44.16 | 39.70 | 40.55 | 52.08 | 38.38 | 40.50 | 82.37 |
| — | -50.0% | -60.8% | -54.5% | -19.6% | -14.0% | -31.8% | +11.8% | +21.1% | +39.1% | +38.2% | +2.0% | +1.3% | -38.7% | +15.1% | -2.0% | -50.8% | +69.8% | -46.5% | +6.9% | +90.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0% | 66.7% | 70.7% | 69.4% | 74.5% | 69.9% | 67.7% | 63.3% | 58.6% | 62.9% | 62.7% | 61.8% | 62.1% | 61.4% | 63.2% | 61.3% | 60.3% | 60.8% | 61.3% | 60.9% | 62.1% |
| — | -4.6% | +4.5% | +9.8% | +27.2% | +11.2% | +7.8% | +2.3% | -5.6% | +2.4% | -0.8% | +0.9% | +2.9% | +1.0% | +3.2% | +0.6% | -2.9% | -2.7% | -2.9% | +0.5% | +12.0% | |
| Operating Margin | 19.8% | 19.1% | 21.6% | 20.6% | 22.8% | 20.7% | 16.2% | 19.2% | 12.9% | 16.0% | 18.1% | 16.7% | 15.0% | 15.8% | 15.3% | 15.2% | 13.8% | 14.5% | 14.7% | 15.1% | 14.6% |
| — | -8.1% | +33.8% | +7.2% | +76.7% | +29.5% | -10.7% | +15.1% | -13.8% | +1.2% | +18.4% | +9.9% | +8.2% | +9.0% | +4.1% | +0.6% | -5.2% | -3.7% | -11.5% | +15.4% | +127.5% | |
| Net Margin | 14.4% | 11.2% | 16.7% | 25.7% | 12.6% | 14.9% | 15.7% | 14.5% | 12.4% | 11.1% | 7.9% | 12.8% | 13.5% | 14.3% | 7.5% | 9.3% | 4.3% | 5.9% | 8.0% | 3.7% | 3.0% |
| — | -24.5% | +6.4% | +77.8% | +1.8% | +33.8% | +99.2% | +12.8% | -8.3% | -22.0% | +4.8% | +38.3% | +213.3% | +141.0% | -6.4% | +152.6% | +43.7% | -58.5% | +32.6% | -70.4% | -46.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.4% | 2.3% | 3.5% | 5.3% | 2.8% | 3.3% | 3.5% | 3.0% | 2.6% | 2.3% | 1.6% | 2.5% | 2.6% | 2.7% | 1.5% | 1.8% | 0.8% | 1.1% | 1.5% | 0.7% | 0.6% |
| — | -30.6% | +0.6% | +74.3% | +5.4% | +44.6% | +121.3% | +21.9% | +1.1% | -15.8% | +7.7% | +41.4% | +227.9% | +148.7% | -3.5% | +164.4% | +39.9% | -58.3% | +30.2% | -69.7% | -42.3% | |
| ROA | 6.9% | 1.3% | 2.0% | 3.0% | 1.5% | 1.8% | 1.9% | 1.7% | 1.5% | 1.2% | 0.9% | 1.4% | 1.5% | 1.5% | 0.8% | 1.0% | 0.4% | 0.6% | 0.8% | 0.3% | 0.3% |
| — | -28.9% | +4.3% | +79.2% | +5.9% | +43.6% | +121.0% | +23.2% | +0.3% | -16.3% | +8.2% | +43.2% | +235.2% | +154.2% | +0.8% | +179.5% | +48.2% | -55.9% | +34.5% | -68.9% | -40.5% | |
| ROIC | 8.8% | 2.0% | 2.4% | 2.3% | 2.6% | 2.3% | 1.8% | 2.0% | 1.4% | 1.7% | 1.9% | 1.7% | 1.5% | 1.5% | 1.5% | 1.5% | 1.3% | 1.3% | 1.4% | 1.4% | 1.4% |
| — | -14.2% | +33.4% | +12.4% | +84.6% | +32.6% | -6.8% | +19.8% | -6.0% | +13.8% | +28.4% | +15.9% | +16.5% | +15.9% | +11.2% | +7.2% | -9.4% | -7.5% | -18.3% | +16.9% | +151.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.51 | 0.46 | 0.50 | 0.42 | 0.51 | 0.51 | 0.53 | 0.52 | 0.51 | 0.54 | 0.53 | 0.55 | 0.49 | 0.49 | 0.51 | 0.52 | 0.53 | 0.51 | 0.54 | 0.58 | 0.57 |
| — | -9.4% | -5.5% | -19.0% | +0.2% | -5.1% | +0.1% | -4.4% | +4.2% | +10.5% | +3.8% | +5.5% | -8.0% | -4.0% | -5.4% | -10.6% | -7.1% | -11.9% | -8.9% | -3.7% | -8.6% | |
| Debt / EBITDA | 2.33 | 12.21 | 8.23 | 7.75 | 7.90 | 8.65 | 10.41 | 9.59 | 11.90 | 11.49 | 10.34 | 11.60 | 10.90 | 10.83 | 11.14 | 11.71 | 12.49 | 12.01 | 12.26 | 13.25 | 12.65 |
| — | +41.1% | -20.9% | -19.2% | -33.6% | -24.7% | +0.7% | -17.4% | +9.2% | +6.1% | -7.2% | -0.9% | -12.8% | -9.8% | -9.1% | -11.6% | -1.3% | -9.4% | +0.2% | -11.9% | -38.6% | |
| Current Ratio | 1.62 | 1.36 | 1.24 | 1.90 | 1.62 | 1.51 | 1.37 | 1.45 | 1.08 | 1.48 | 1.61 | 1.66 | 1.32 | 1.42 | 1.29 | 1.40 | 1.51 | 1.45 | 1.31 | 1.18 | 1.48 |
| — | -9.5% | -9.6% | +31.0% | +49.5% | +1.7% | -14.9% | -12.9% | -18.1% | +4.4% | +25.0% | +19.2% | -12.8% | -2.0% | -1.4% | +17.9% | +2.5% | -6.4% | -21.1% | -34.1% | -18.7% | |
| Quick Ratio | 1.08 | 0.81 | 0.74 | 1.22 | 1.08 | 0.96 | 0.82 | 0.88 | 0.64 | 1.02 | 1.14 | 1.14 | 0.82 | 0.90 | 0.80 | 0.89 | 1.02 | 0.95 | 0.86 | 0.78 | 1.10 |
| — | -15.6% | -10.2% | +37.9% | +67.5% | -5.6% | -28.3% | -22.8% | -21.4% | +13.5% | +43.6% | +27.8% | -20.2% | -5.3% | -7.1% | +14.9% | -7.1% | -17.8% | -34.4% | -43.7% | -24.1% | |
| Interest Coverage | 10.70 | 9.79 | 12.04 | 13.91 | 10.62 | 11.79 | 11.47 | 10.25 | 5.20 | 9.05 | 6.19 | 9.44 | 8.54 | 10.07 | 7.00 | 7.63 | 7.23 | 4.75 | 6.38 | 1.53 | 2.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BSX stock.
Boston Scientific Corporation's current P/E is 17.8x. The average P/E over the last 4 quarters is 28.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Boston Scientific Corporation's current operating margin is 19.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Boston Scientific Corporation's business trajectory between earnings reports.